Description of the medicine: Dibunolum

Dibunolum (see also Tocopherol acetate). 2, 6-Di-t-butyl-4-methylphenol.

Synonyms: Butyloxytoluene, Jonal.

White or white with a slightly yellowish tinge crystalline powder. Almost nerastvorim in water, easily soluble in alcohol.

Dibunol - one of the main representatives of the group of antioxidants, i.e. Compounds that are inhibitors of free radical reactions.

A number of studies have shown that various pathological conditions are caused by disorders of free radical reactions in membrane lipids, which leads to an intensification of lipid peroxidation. In recent years, it has been established that endogenous compounds inhibiting lipid peroxidation (LPO) are formed in the body. One such compound, the superoxide dismutase enzyme, is an acceptor of free oxygen radicals, which inhibits the peroxidation of lipids and proteins. It is believed in this connection that superoxide dismutase can be used in the treatment and prevention of various diseases.

At the same time, there are exogenous (pharmacological) substances actively inhibiting LPO (antioxidants), correcting oxygen-dependent pathological conditions. At the same time, they are also antihypoxic.

One of the main antioxidants is tocopherol acetate (see).

Dibunol, which has a pronounced antiradical (antioxidant) activity, was first proposed for topical application in the form of 10% liniment in the treatment of cancer and papillomatosis of the bladder. Currently, it is also used for cystitis, superficial burns, frostbites I - II degree, long-term healing trophic and radiation ulcers, sluggishly granulating wounds.

In connection with the antioxidant and antihypoxic properties of dibunol, its effectiveness in various diseases accompanied by activation of lipid peroxidation is studied.

Dibunol is used in the form of intravesical instillations (10% liniment) with diseases of the bladder and externally (5% liniment) with burns, frostbites, ulcers, etc.

For intravesical instillations immediately before use, 10 g of 10% of the dibunol liniment is diluted with 24-30 ml of 0.25-1% novocaine solution to a consistency suitable for intravesical administration, and then the resulting solution (35-40 ml) is injected through the catheter into the pre-emptied urinary bubble. Before instillation it is recommended to wash the bladder with an antiseptic solution. The patient should keep the dibunol in the bladder until the next urination, preferably 2 to 3 hours. In cases of painful reaction to the introduction of a catheter in the absence of mechanical narrowing of the urethra, dibunol administration through the urethra under pressure (according to Jean) is permissible.

Instillations of the drug are produced daily. To obtain an anti-inflammatory effect, 10 to 15 instillations are required, and sometimes less, and for the antitumor effect, at least 25.